

"Express Mail" Label No. EV 566969805 US  
Date of Deposit January 17, 2005

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By:   
Aaron Hokamura

**Rec'd PCT/PTO** 18 JAN 2006  
**PATENT**

Attorney Docket No.: 082368-003700US  
Client Reference No.: ONC-A0218P1-US

#4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

NAKAMURA and FURUKAWA

Application No.: 10/529,523

Filed:

Int'l Application No.: PCT/JP03/10338

Int'l Filing Date: August 14, 2003

For: METHOD FOR TREATING OR  
PREVENTING METASTASIS OF  
COLORECTAL CANCERS

Examiner:

Art Unit:

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

The attached references were cited in the International Search Report in a corresponding application. A copy of the Search Report is enclosed.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
60679859 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/529,523
Int'l Filing Date	August 14, 2003
First Named Inventor	Nakamura, Yusuke, et. al.
Art Unit	
Examiner Name	
Attorney Docket Number	082368-003700US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	WO	02/21996	A2/A3	03-21-2002	Eos Biotechnology, Inc.		<input type="checkbox"/>
	AB	WO	03/029273	A2/A3	04-10-2003	Whitehead Institute for Biomedical Research		<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60679859 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/529,523
		Int'l Filing Date	August 14, 2003
		First Named Inventor	Nakamura, Yusuke, et. al.
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	082368-003700US	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	LI, Meihua <i>et al.</i> ; "Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray"; <u>International Journal of Oncology</u> ; 2004; pp. 305-312; Vol. 24.	
	AD	PEEPER, Daniel S. <i>et al.</i> ; "A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence"; <u>Nature Cell Biology</u> ; February 2002; pp. 148-153; Vol. 4	
	AE	SUZUKI, Mitsuhiro <i>et al.</i> ; "A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer"; <u>Oncogene</u> ; 1998; pp. 853-865; Vol. 17.	
	AF	YANAGAWA, Rempei <i>et al.</i> ; "Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray"; <u>Neoplasia</u> ; 2001; pp. 395-401; Vol. 3, No. 5.	
	AG	YANAGAWA, Rempei <i>et al.</i> ; "Identification of genes associated with liver metastasis of colorectal cancer by means of cDNA microarray"; <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> ; March 24, 2001; pg. 59, Abstract No. 313; Vol 42	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60679859 v1